TxCell Share Price

Stocks

TXCL

FR0010127662

Biotechnology & Medical Research

Real-time 5-day change 1st Jan Change
- EUR -.--% Intraday chart for TxCell -.--% +67.53%
Manager TitleAgeSince
Chief Operating Officer 50 -
Corporate Officer/Principal - -
Corporate Officer/Principal - -
Director TitleAgeSince
Chairman - 12/02/2019
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 0
-4.31%-2.14%+65.79%+103.90% 7.21TCr
-4.19%+18.35%+52.79%+86.77% 6.59TCr
-3.22%+21.19%+1.75%-8.28% 2.93TCr
-1.42%+0.19%-5.99%+461.25% 2.75TCr
-4.71%+7.67%+47.63%+18.25% 2.67TCr
-1.81%+4.19%+34.52%-17.69% 2.01TCr
+5.36%-1.67%+270.18%+415.10% 1.82TCr
-2.79%+0.48%+12.09%+562.03% 1.64TCr
+0.87%+6.46%+41.21%+150.80% 1.34TCr
Average -1.58%+8.55%+57.77%+196.90% 3.22TCr
Weighted average by Cap. -2.78%+8.78%+54.39%+153.95%
Logo TxCell
TxCell is a biotechnology company which develops platforms for innovative customized cell immunotherapies from regulatory T cells (Treg) for the treatment of severe chronic inflammatory, autoimmune diseases and transplant rejection. TxCell is developing a platform for genetically modified T-cells, the CAR-Tregs. TxCell plans to release preclinical proof-of-concept data in 2017 and start a first clinical study by the end of 2018.
Employees
-
  1. Stock Market
  2. Stocks
  3. TXCL Stock